Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lifts CMC Markets price target ahead of results

(Sharecast News) - Canaccord Genuity lifted its price target on CMC Markets on Friday to 222p from 192p as it updated forecasts ahead of FY25 results on 5 June to reflect expected trading performance into the end of the year and market conditions in FY26 year to date. Canaccord said it expects that FY26 has started very strongly for the CFD trading business given the significant spike in volatility at the beginning of April.

Its adjusted diluted earnings per share forecasts are +17%/+61%/-4% versus current Bloomberg consensus in FY25/26/27, respectively. Canaccord said it doesn't appear that the consensus has yet adjusted to reflect recent market conditions.

"As we have written previously, the lack of disclosure at CMC compounds the challenge of forecasting an inherently volatile business model," it said. "We forecast a FY25-27 adjusted diluted EPS compound annual growth rate of -4%, with FY27 adj. dil. EPS the same as FY22."

Canaccord said the forecast dividend yield of 6% in FY26 falling to 5% in FY27 is not standout, and given the 50% payout policy is subject to volatility.

"The company is currently operating without a CFO and we understand has no plans to fill the role, which is a source of intrigue and concern for us," it said.

"Our long-held view for the CFD sector is to take profits when periods of high volatility deliver super-normal returns, and conversely buy when volatility is low.

"However, even in normal market conditions, give the concerns we have expressed we would rather look elsewhere than CMC for exposure to CFD/leveraged trading."

Canaccord maintained its 'sell' rating on the stock.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.